Vivos Therapeutics jumps as FDA clears sleep apnea device

Vivos Therapeutics

04/01/2023 13:53

** Shares of medical device maker Vivos Therapeutics Inc 
 VVOS.O  rise 43.2% to $1.06 premarket 
    ** The U.S. FDA clears the use of VVOS' device to treat
mild-to-moderate obstructive sleep apnea (OSA)
    ** OSA is the most common sleep-related breathing disorder
which occurs when throat muscles intermittently relax and block
the airway during sleep   
    ** Shares fell nearly 70% in the past 12 months 
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))